

**Immuno-Oncology Therapies for the Treatment of Advanced Endometrial Cancer:
Which of Your Patients May Benefit from Their Use?**

Resource	Address
Henley SJ, Miller JW, Dowling NF, Benard VB, Richardson LC. Uterine cancer incidence and mortality - United States, 1999-2016. <i>MMWR Morb Mortal Wkly Rep.</i> 2018;67:1333-1338.	https://pubmed.ncbi.nlm.nih.gov/30521505/
The Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. <i>Nature.</i> 2013;497:67-73.	https://pubmed.ncbi.nlm.nih.gov/23636398/
Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). <i>J Clin Oncol.</i> 2020;38:3841-3850.	https://pubmed.ncbi.nlm.nih.gov/33078978/
Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): Updated overall survival analysis. <i>Clin Cancer Res.</i> 2020;26:3928-3935.	https://pubmed.ncbi.nlm.nih.gov/32601075/
MacKay HJ, Levine DA, Bae-Jump VL, et al. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget.</i> 2017;8:84579-84594.	https://pubmed.ncbi.nlm.nih.gov/29137450/
Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. <i>Ann Oncol.</i> 2019;30:1232-1243.	https://pubmed.ncbi.nlm.nih.gov/31056702/
Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study. <i>J Clin Oncol.</i> 2017;35:2535-2541.	https://pubmed.ncbi.nlm.nih.gov/28489510/

<p>Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. <i>J Clin Oncol.</i> 2019;38:1-10.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31682550/</p>
<p>Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: A nonrandomized phase 1 clinical trial. <i>JAMA Oncol.</i> 2020;6:1766-1772.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/33001143/</p>
<p>Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. <i>J Clin Oncol.</i> 2019;37:2786-2794.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31461377/</p>
<p>Wang D, Lin J, Yang X, et al. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>J Hematol Oncol.</i> 2019;12:42.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31014381/</p>
<p>Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncol.</i> 2019;20:711-718.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30922731/</p>
<p>Makker V, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. <i>J Clin Oncol.</i> 2020;38:2981-2992.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32167863/</p>
<p>Makker V, Colombo N, Casado Herráez A, et al. O008/#785 A multicenter, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. <i>Int J Gynecol Cancer.</i> 2021;31:A4-A5.</p>	<p>https://ijgc.bmj.com/content/31/Suppl_4/A4.2</p>
<p>Schneider BJ, Naidoo J, Santomaso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39:4073-4126.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34724392/</p>
<p>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. <i>N Engl J Med.</i> 2018;378:158-168.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/29320654/</p>

<p>Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. <i>J Clin Oncol.</i> 2015;33:2092-2099.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/25918278/</p>
<p>Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>JAMA Oncol.</i> 2018;4:1721-1728.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30242316/</p>